U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H11ClN2O5S.ClH
Molecular Weight 367.205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FUROSEMIDE HYDROCHLORIDE

SMILES

Cl.NS(=O)(=O)C1=C(Cl)C=C(NCC2=CC=CO2)C(=C1)C(O)=O

InChI

InChIKey=NXDBFIUCDBZBPP-UHFFFAOYSA-N
InChI=1S/C12H11ClN2O5S.ClH/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19;/h1-5,15H,6H2,(H,16,17)(H2,14,18,19);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H11ClN2O5S
Molecular Weight 330.744
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/furosemide.html

Furosemide, a sulfonamide-type loop diuretic structurally related to bumetanide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic. Furosemide is sold under the brand name Lasix among others.

CNS Activity

Curator's Comment: furosemide did not cross the barrier

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P05370
Gene ID: 24377.0
Gene Symbol: G6pdx
Target Organism: Rattus norvegicus (Rat)
0.13 mM [IC50]
Target ID: P85968
Gene ID: 1.00360176E8
Gene Symbol: Pgd
Target Organism: Rattus norvegicus (Rat)
0.14 mM [IC50]
0.08 mM [IC50]
52.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LASIX

Approved Use

Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

1966
Primary
LASIX

Approved Use

Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral Furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

1966
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1315.34 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3014.77 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.1 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.2%
FUROSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
major
yes (co-administration study)
Comment: probe drug substrate for renal transporters OAT1 and OAT3; clinical investigation of a probe drug cocktail containing substrates of key drug transporters (digoxin, furosemide, metformin and rosuvastatin)
Page: 9.0
major
yes (co-administration study)
Comment: probe drug substrate for renal transporters OAT1 and OAT3; clinical investigation of a probe drug cocktail containing substrates of key drug transporters (digoxin, furosemide, metformin and rosuvastatin)
Page: 9.0
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: The time-averaged non-renal clearance (CLNR) of furosemide tended to be faster (but not significantly so) among smokers (3-methylcholanthrene (3-MC) type; a main inducer of CYP1A1/2
Page: 1.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2.
2001-07-27
Sensitivity of synaptic GABA(A) receptors to allosteric modulators in hippocampal oriens-alveus interneurons.
2001-07
The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
2001-06
Urolithiasis in the low birth weight infant: the role and efficacy of extracorporeal shock wave lithotripsy.
2001-06
Angiotensin converting enzyme inhibition worsens the excretory phase of diuretic renography for obstructive hydronephrosis.
2001-06
Supranormal differential renal function is real but may be pathological: assessment by 99m technetium mercaptoacetyltriglycine renal scan of congenital unilateral hydronephrosis.
2001-06
Dynamic characteristics and underlying mechanisms of renal blood flow autoregulation in the conscious dog.
2001-06
Perturbation of the pump-leak balance for Na(+) and K(+) in malaria-infected erythrocytes.
2001-06
[Extrarenal effects of furosemide on normal and ischemic cerebral tissue in the rat].
2001-05-11
Ethanol-induced swelling in neonatal rat primary astrocyte cultures.
2001-05-11
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
2001-05-05
Heterogeneous susceptibility of GABA(A) receptor-mediated IPSCs to depolarization-induced suppression of inhibition in rat hippocampus.
2001-05-01
Natriuresis and "dilutional" hyponatremia after infusion of glycine 1.5%.
2001-05
Taurocholic acid-induced secretion in normal and cystic fibrosis mouse ileum.
2001-05
Pulmonary edema: new insight on pathogenesis and treatment.
2001-05
Effects of inhalation of albuterol sulphate, ipratroprium bromide and frusemide on breathing mechanics and gas exchange in healthy exercising horses.
2001-05
Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide.
2001-05
Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion.
2001-05
Nephrocalcinosis induced by furosemide in an adult patient with incomplete renal tubular acidosis.
2001-05
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
2001-05
Diamidine compounds: selective uptake and targeting in Plasmodium falciparum.
2001-05
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
2001-05
Interaction of serotonin and cholecystokinin in the lateral parabrachial nucleus to control sodium intake.
2001-05
Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo).
2001-04-13
Deterioration of left ventricular chamber performance after bed rest : "cardiovascular deconditioning" or hypovolemia?
2001-04-10
Maxi K+ channels co-localised with CFTR in the apical membrane of an exocrine gland acinus: possible involvement in secretion.
2001-04
Effect of salicis cortex extract on human platelet aggregation.
2001-04
Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55.
2001-04
Acute effects of the anti-inflammatory cyclooxygenase-2 selective inhibitor, flosulide, on renal plasma flow and glomerular filtration rate in rats.
2001-04
Furosemide-probenecid interaction as a laboratory exercise for undergraduate education in clinical pharmacology.
2001-04
Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.
2001-04
Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure.
2001-04
ATP stimulates calcium-dependent glutamate release from cultured astrocytes.
2001-04
Systemic sclerosis (scleroderma). A case of recovery of cardiomyopathy after vitamin E treatment.
2001-04
Chronic tubulointerstitial nephritis and distal renal tubular acidosis in a patient with frusemide abuse.
2001-04
[Generalized edema following insulin treatment of newly diagnosed diabetes mellitus].
2001-03-20
Pediatric renal transplantation: anesthesia and perioperative complications.
2001-03
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
2001-03
The appropriateness of drug use in an older nondemented and demented population.
2001-03
Multi-slice CT urography after diuretic injection: initial results.
2001-03
Humoral hypercalcemia of malignancy in squamous cell carcinoma of the skin: parathyroid hormone--related protein as a cause.
2001-03
Estimation of the probability for exceeding a threshold concentration of furosemide at various intervals after intravenous administration in horses.
2001-03
Effect of furosemide on basal lamina anionic sites in guinea pig labyrinth.
2001-03
Statistical evaluation of the regulatory guidelines for use of furosemide in race horses.
2001-03
Haemoconcentration, shear-stress increase and carotid artery diameter regulation after furosemide administration in older hypertensives.
2001-03
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Frusemide or nitrates in acute left ventricular failure.
2001-01
Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
2001-01
The loop diuretic torasemide interferes with endothelin-1 actions in the aorta of hypertensive rats.
2001
Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth.
2001
Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.
2001
Patents

Sample Use Guides

The usual initial dose of LASIX is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (eg, at 8 am and 2 pm). The dose of LASIX may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states.
Route of Administration: Oral
There was a significant reduction in levels of TNF-alpha and IL-6 at a furosemide concentration of 0.5 x 10(-2) M and a reduction in IL-8 levels at 10(-2) M in human peripheral blood mononuclear cells.
Substance Class Chemical
Created
by admin
on Wed Apr 02 13:51:04 GMT 2025
Edited
by admin
on Wed Apr 02 13:51:04 GMT 2025
Record UNII
95B2QX2E2W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4-CHLORO-2-(((FURAN-2-YL)METHYL)AMINO)-5-SULFAMOYLBENZOIC ACID HYDROCHLORIDE
Preferred Name English
FUROSEMIDE HYDROCHLORIDE
Common Name English
BENZOIC ACID, 5-(AMINOSULFONYL)-4-CHLORO-2-((2-FURANYLMETHYL)AMINO)-, HYDROCHLORIDE (1:1)
Systematic Name English
BENZOIC ACID, 5-(AMINOSULFONYL)-4-CHLORO-2-((2-FURANYLMETHYL)AMINO)-, MONOHYDROCHLORIDE
Systematic Name English
Code System Code Type Description
PUBCHEM
54583777
Created by admin on Wed Apr 02 13:51:04 GMT 2025 , Edited by admin on Wed Apr 02 13:51:04 GMT 2025
PRIMARY
FDA UNII
95B2QX2E2W
Created by admin on Wed Apr 02 13:51:04 GMT 2025 , Edited by admin on Wed Apr 02 13:51:04 GMT 2025
PRIMARY
CAS
42461-27-8
Created by admin on Wed Apr 02 13:51:04 GMT 2025 , Edited by admin on Wed Apr 02 13:51:04 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY